Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL
Blood · 24.04.2025 · 145 (17) · 1890-1902
DOI: 10.1182/blood.2024026381 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, erschienen am 24.04.2025. Verfasst von Weina Zhang und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Guangzhou Medical University Affiliated Women and Children's Medical Center, Guangzhou, China. Hauptthemen laut MEDLINE: Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
We evaluated the prognostic and therapeutic significance of measurable residual disease (MRD) during remission induction in pediatric patients with acute lymphoblastic leukemia (ALL). In the Chinese Children Cancer Group ALL 2015 protocol, 7640 patients were categorized into low-, intermediate-, or high-risk groups based on clinical and genetic features. Final risk classification was determined by assessing MRD using flow cytometry on days 19 and 46 of remission induction with additional intensified chemotherapy for day 19 MRD ≥1%. Patients with B-ALL with negative MRD (<0.01%) on day 19 or day 46 had significantly better 5-year event-free survival (EFS) than those with MRD of between 0.01% and 0.99% who, in turn, had better EFS than patients with MRD of ≥1%. Provisional low-risk patients with day 19 MRD ≥1% but negative day 46 MRD who were reclassified as intermediate risk had a 5-year EFS that was comparable with that of low-risk patients with day 19 MRD of 0.3% to 0.99% and negative day 46 MRD (82.5% vs 83.0%) and better EFS than provisional low-risk patients with MRD on both days (83.0% vs 72.6%; P < .001). Similarly, patients with provisional intermediate-risk B-ALL with day 19 MRD ≥1% but negative day 46 MRD who received additional therapy had better 5-year EFS than those with day 19 MRD between 0.3% and 0.99% (70.7% vs 53.0%; P < .001). Among low-risk patients with negative day 46 MRD, those with negative day 19 MRD had superior EFS than those with positive day 19 MRD (91.7% vs 86.1%; P < .001). Optimal use of day 19 MRD could improve individualized treatment and outcomes. This trial was registered at www.chictr.org.cn as #ChiCTR-IPR-14005706.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Hematology/Oncology, Guangzhou Medical University Affiliated Women and Children's Medical Center, Guangzhou, China.
- Department of Hematology/Oncology, Key Laboratory of Pediatric Hematology and Oncology of China Ministry of Health, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, National Children…
- State Key Laboratory of Experimental Hematology and Division of Pediatric Blood Diseases Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,…
- Department of Hematology/Oncology, Chongqing Medical University Affiliated Children's Hospital, Chongqing, China.
- Department of Hematology/Oncology, Children's Hospital of Soochow University, Suzhou, China.
- Department of Pediatrics, Key Laboratory of Birth Defects and Related Disease of Women and Children,West China Second University Hospital, Sichuan University, Ministry of Education, Chengdu, China.
ORCID-Profile: Jiaoyang Cai, Xiaofan Zhu, Shuhong Shen, Chi-Kong Li, Ching-Hon Pui
Zitieren
APA
Zhang, W., Cai, J., Wang, X., Ma, Y., Zhu, X., Yu, J., Xiao, P., Gao, J., Fang, Y., Liang, C., Li, X., Zhou, F., Zhai, X., Xu, X., Tian, X., Liu, A., Wang, N., Zhu, J., Wang, L., …, & Pui, C. H. (2025). Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL. Blood, 145(17), 1890-1902. https://doi.org/10.1182/blood.2024026381
Vancouver
Zhang W, Cai J, Wang X, Ma Y, Zhu X, Yu J, et al. Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL. Blood. 2025;145(17):1890-1902. doi:10.1182/blood.2024026381
BibTeX
@article{Zhang2025,
author = {Zhang, Weina and Cai, Jiaoyang and Wang, Xiang and Ma, Yani and Zhu, Xiaofan and Yu, Jie and Xiao, Peifang and Gao, Ju and Fang, Yongjun and Liang, Changda and Li, Xue and Zhou, Fen and Zhai, Xiaowen and Xu, Xiaoxiao and Tian, Xin and Liu, Aiguo and Wang, Ningling and Zhu, Jiashi and Wang, Lingzhen and Cheng, Frankie Wai-Tsoi and Yang, Liangchun and Zhang, Ge and Cheng, Cheng and Yang, Jun J and Shen, Shuhong and Li, Chi-Kong and Li, Benshang and Jiang, Hua and Pui, Ching-Hon},
title = {Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL},
journal = {Blood},
year = {2025},
volume = {145},
number = {17},
pages = {1890--1902},
doi = {10.1182/blood.2024026381}
}
EUVIMED